Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
PwC notes that the next phase of the obesity drug market will likely be defined by expanded indications, improved delivery methods and therapies offering better long-term patient adherence
This receptor is widely distributed throughout various tissues involved in endocrine and metabolic regulation
Once-monthly maridebart cafraglutide for the treatment of obesity - a phase 2 trial
Presented for research literature review only Ding H et al
Barritt AS, Marshman E, Noureddin M
US$ 29.61
US$ 29.77
US$ 24.14
US$ 26.92
US$ 26.74
US$ 23.98
